BioTuesdays

Zucara receives additional JDRF funding for Phase 2 study

Zucara Logo

Closely-held Zucara Therapeutics received an additional $2-million in funding from JDRF (Juvenile Diabetes Research Foundation) to support Zucara’s planned Phase 2a study of the effect of its ZT-01 on nocturnal hypoglycemia events in Type 1 diabetes mellitus.

Zucara expects to begin patient dosing in the third quarter of 2023. JDRF has been a long-time partner of Zucara, supporting the development of ZT-01 from early discovery studies to the planned Phase 2 study.

The latest funding “underscores JDRF’s prioritization of advancing adjunctive therapies to insulin, reflecting a continuing unmet need for T1D patients,” Richard Liggins, Ph.D. and CSO of Zucara, said in a statement.

“We are hopeful that the ZONE study will demonstrate that ZT-01 can prevent potentially dangerous and disruptive low blood glucose levels overnight, and lead to the first therapeutic to treat this unintended consequence of insulin therapy,” he added.

POWERED BY

Stay Ahead in Healthcare & Life Sciences